ISSN:
1432-1041
Schlagwort(e):
primidone
;
viral hepatitis
;
single-dose kinetics
;
primidone metabolism
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Chemie und Pharmazie
,
Medizin
Notizen:
Summary The pharmacokinetics of primidone (PRM) after oral administration of a single 500 mg dose was studied in 7 patients with acute viral hepatitis and 7 healthy control subjects. The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0±3.1 h and 42±14 ml·h−1·kg−1, respectively (mean ± SD) and did not differ significantly from the values in the controls (half-life 17.0±2.4 h; clearance 35±8 ml·h−1·kg−1). The metabolite phenylethylmalonamide (PEMA) was detected in the serum of all normal subjects within 2–24 h. By contrast, serum levels of this metabolite were undetectable (〈2 umol/l) in all but one of the patients. Serum levels of phenobarbital (PB) remained below the limit of detection (〈2 µmol/l) in all subjects. The findings indicate that accumulation of PRM with its attendant toxicity is unlikely to occur in epileptic patients who develop acute viral hepatitis, despite evidence that the metabolism of the drug is affected by this condition. The possibility of impaired conversion to PB and its implications are discussed.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1007/BF00549596
Permalink